Quad M Solutions, Inc., on August 24, 2022, at which meeting all of the members of the Board were present in person and/or telephonically, the Board unanimously approved the appointment of Drs. Michael Fonstein, Ph.D. and Yakov Kogan, Ph.D. to the Company's Board. Dr. Michael Fonstein PhD, age 62, Director: Dr. Michael Fonstein was appointed as a director of Quad M Solutions, Inc., an Idaho corporation on August 24, 2022.

In 2021, Dr. Fonstein founded and has served as Chairman and CEO of BioSynthetic Machines, Inc., an Illinois-based company organized under the laws of Nevada (“BSMI”). Dr. Fonstein has also founded and served as CEO of several biotechnology companies including: Integrated Genomics, Inc., Cleveland Biolabs, Inc., n/k/a Statera Biopharma, Inc. (NASDAQ: STAB), a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis; Accelerated Pharma, Inc. and Panacela Labs, Inc., private Delaware companies. Through his management, several of these companies developed from start-ups to established and successful ventures, securing multiple rounds of private and public financing including R&D and service contracts with Fortune 100 companies and procurement of governmental grants among other funding.

Dr. Fonstein has extensive business and scientific experience and actively involved day-to-day operations as well as strategic corporate planning of the businesses he founded. Dr. Fonstein started his career as a research scientist. During his years in academia, Dr. Fonstein became a recognized expert in microbial genomics and system biology, founded a genomic center at the University of Chicago, and published numerous papers in top peer-reviewed scientific journals.

Most recently Dr. Fonstein served as a Computational Scientist at U.S. Department of Energy's Argonne National Laboratory. Dr. Yakov Kogan, Ph.D., age 49, Director: Dr. Kogan was appointed as a director of Quad M Solutions, Inc., an Idaho corporation (OTC: MMMM) on August 24, 2022. Dr. Kogan co-founder and has served as Chief Business Officer of BSMI from 2021 to the present.

Prior to joining BSMI, Dr. Kogan served as a senior consultant to several private and public biotechnology companies including: serving as a CEO and director of Cleveland BioLabs, Inc., n/k/a Cytocom, Inc. (NASDAQ: CBLI) together with Dr. Fonstein, which they had built from its inception to an operation with over 50 full-time employees, while securing upward of $150 million in equity financing. During his tenure with CBLI, Dr. Kogan played a significant role in establishing operations, hiring senior operations staff, and executing the Company's initial public offering on NASDAQ. Prior to CBLI, Dr. Kogan served as Director for Business Development at Integrated Genomics, a private company located in Chicago, IL, where he was responsible for commercial sales and expansion of the company's capital base.

Prior to his position as Director of Business Development, Dr. Kogan worked as a Group Leader/Senior Scientist at Integrated Genomics as well as at ThermoGen, Inc. In addition, Dr. Kogan was a Research Associate at the University of Chicago, where he led the execution of several sophisticated microbial genome sequencing projects.